Holocene

Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, May 9, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023.
  • “We are excited about the continued clinical progress of our lead asset ADI-001,” said Chen Schor, President and Chief Executive Officer of Adicet.
  • The Company is preparing to initiate its first potential pivotal study with ADI-001 in the fourth quarter of 2023.
  • Financial Results for First Quarter 2023:
    Research and Development (R&D) Expenses: R&D expenses were $26.8 million for the three months ended March 31, 2023, compared to $13.5 million during the same period in 2022.

Armada Hoffler Reports First Quarter 2023 Results

Retrieved on: 
Tuesday, May 9, 2023

Announced major off market, mixed-use acquisition of The Interlock in West Midtown, Atlanta

Key Points: 
  • Announced major off market, mixed-use acquisition of The Interlock in West Midtown, Atlanta
    VIRGINIA BEACH, Va., May 09, 2023 (GLOBE NEWSWIRE) -- Armada Hoffler Properties, Inc. (NYSE: AHH) today announced its results for the quarter ended March 31, 2023 and provided an update on current events.
  • Maintained 2023 full-year Normalized FFO guidance of $1.23 to $1.27 per diluted share at the Company's previous guidance range.
  • Lease rates on first quarter retail lease renewals increased 10.1% on a GAAP basis and 6.8% on a cash basis.
  • “We continue to see our best in class properties, located in desirable markets, yield impressive results in most any economic climate,” said Louis Haddad, President & CEO of Armada Hoffler.

Aqua Metals Produces High-Value Minerals at Pilot Plant, Secures Site to Expand Commercial Operations, During First Quarter of 2023

Retrieved on: 
Thursday, May 4, 2023

Secured a five-acre campus site, with space to process more than 20 million pounds of lithium-ion batteries annually, including an existing facility to expand operations.

Key Points: 
  • Secured a five-acre campus site, with space to process more than 20 million pounds of lithium-ion batteries annually, including an existing facility to expand operations.
  • Strengthened balance sheet with the final $12 million payment received from Comstock Inc. for previously owned property providing sufficient cash balances to execute 2023 plans.
  • Upon successful development, this transaction represents a large, multi-million dollar revenue opportunity for Aqua Metals.”
    During the first quarter of 2023, Aqua Metals continued to focus on its ability to recycle metals found in lithium-ion batteries.
  • A telephone replay will be available until November 2, 2023, by dialing 877-660-6853 or 201-612-7415 and using pin number 13738033.

Reconstructing ancient bacterial genomes can revive previously unknown molecules – offering a potential source for new antibiotics

Retrieved on: 
Thursday, May 4, 2023

These metabolites provide the microbes major evolutionary advantages, such as allowing them to interact with one another or their environment and helping defend against different threats.

Key Points: 
  • These metabolites provide the microbes major evolutionary advantages, such as allowing them to interact with one another or their environment and helping defend against different threats.
  • Because of the diverse functions bacterial natural products have, many have been used as medical treatments such as antibiotics and anti-cancer drugs.
  • By generating previously unknown chemical compounds from the reconstructed genomes of ancient bacteria, our newly published research provides a proof of concept for the potential use of fossil microbes as a source of new drugs.

Reconstructing ancient genomes

    • Such genes are difficult to detect and reconstruct from ancient DNA because very old genetic material breaks down over time, fragmenting into thousands or even millions of pieces.
    • We sequenced billions of such ancient DNA fragments, then improved a bioinformatic process called de novo assembly to digitally order the ancient DNA fragments in stretches of up to 100,000 nucleotides long – a 2,000-fold improvement.
    • This cluster bore the molecular hallmarks of very ancient DNA and belonged to the bacterial genus Chlorobium, a group of green sulfur bacteria capable of photosynthesis.
    • By reconstructing these ancient compounds, our findings highlight how archaeological samples could serve as new sources of natural products.

Mining ancient natural products

    • Because the environments they inhabit today differ from those of their ancestors, microbes today likely produce different natural products than ancient microbes from tens of thousands of years ago.
    • Human lifestyles also dramatically changed over this transition as people began living outside of caves and increasingly experimented with food production.
    • By reconstructing microbial genomes from archaeological samples, scientists can tap into the hidden diversity of natural products that would have otherwise been lost over time, increasing the number of potential sources from which they can discover new drugs.

Scaling up ancient molecules

    • To tap into the vast diversity of chemical compounds encoded in ancient DNA, we now need to streamline our methodology to be less labor-intensive.
    • We are currently optimizing and automating our process to identify biosynthetic genes in ancient DNA more quickly and reliably.
    • Although we can recreate ancient molecules, their biological and ecological roles are difficult to decipher.
    • Whether or not the functions of these compounds have remained the same in the modern relatives of ancient microbes remains to be tested.

Brightcove Announces Financial Results for First Quarter Fiscal Year 2023

Retrieved on: 
Wednesday, May 3, 2023

Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the first quarter ended March 31, 2023.
  • First Quarter 2023 Financial Highlights:
    Revenue for the first quarter of 2023 was $49.1 million, a decrease of 8% compared to $53.4 million for the first quarter of 2022.
  • Loss from operations was $10.7 million for the first quarter of 2023, compared to loss from operations of $2.0 million for the first quarter of 2022.
  • Brightcove earnings will be streamed on May 3, 2023, at 5:00 p.m. (Eastern Time) to discuss the Company's financial results and current business outlook.

Ermenegildo Zegna Group Kicks-Off 2023 With Strong First Quarter Revenues1

Retrieved on: 
Thursday, April 20, 2023

Ermenegildo Zegna N.V. (NYSE: ZGN) (“Zegna Group,” the “Group,” “Zegna,” or the “Company”), owner of the ZEGNA and Thom Browne brands, today announced unaudited revenues of €428.3 million for the first quarter of 2023, an increase of 13.4% year-over-year and 13.1% at constant currency.

Key Points: 
  • Ermenegildo Zegna N.V. (NYSE: ZGN) (“Zegna Group,” the “Group,” “Zegna,” or the “Company”), owner of the ZEGNA and Thom Browne brands, today announced unaudited revenues of €428.3 million for the first quarter of 2023, an increase of 13.4% year-over-year and 13.1% at constant currency.
  • Ermenegildo “Gildo” Zegna, Chairman and CEO of the Zegna Group, said: “We started 2023 with an encouraging upswing led by further reopening in the Greater China Region following COVID-19-related restrictions.
  • Zegna Segment: For the first quarter 2023, revenues for the Zegna segment amounted to €319.3 million, growing by 12.6% year-over-year and 11.9% at constant currency.
  • The Group enjoyed particularly strong DTC revenues, which increased 24.9% year-over-year for both ZEGNA and Thom Browne during the first quarter of 2023.

Friday essay: 'I trained to be an engineer ... now I am a pickle seller'. What does migration do to a wife?

Retrieved on: 
Thursday, April 20, 2023

All my life, I have been trained to be an engineer.

Key Points: 
  • All my life, I have been trained to be an engineer.
  • All my life, I have been trained to be an engineer.
  • By the way, how does one collect data when the “subjects” are human?
  • Like this story of Selina (a pseudonym), born in a riverside town near Dhaka – the capital of Bangladesh.
  • She was made the centre of jokes by her friends:
    Hey, here comes our engineer!
  • There was a time when Selina was busy with her daily hectic routine as a civil engineer working in Bangladesh.
  • Just like the other women in her family, who are either a doctor or engineer, she had made a name for herself.

Overeducated, underemployed

    • At the same time, no one guided her or told her how to rebuild her career in this foreign land.
    • According to 2021 census data, 51,491 people in Australia were born in Bangladesh.
    • Bangladeshi Muslim women here have significantly higher educational attainment than the wider Australian female population.
    • The data shows 19.71% of Bangladeshi Muslim women in Australia have a postgraduate degree, compared with 5.41% of women in general.
    • Overall, 22.75% of Bangladeshi Muslim women have a bachelor’s degree, compared with 15.87% of women across the board.
    • Recent ABS statistics show 57% of skilled visa holders have had two or more jobs simultaneously since arrival.

‘Losing myself bit by bit’

    • I met Selina to listen to her financial experiences, to identify any pattern of financial abuse in her spousal relationship.
    • I have met Jasmin and Shimul (both pseudonyms), one a former banker and the other a university lecturer before she migrated.
    • Instead of feeling joy and excitement, [it was] as if I was losing myself bit by bit into the unknown.
    • Instead of feeling joy and excitement, [it was] as if I was losing myself bit by bit into the unknown.
    • Spousal financial abuse thrives when one partner starts manipulating, deceiving or coercing to create or maintain the other partner’s dependency.

‘Do they think I am a robot?’

    • Did you learn to make pickles before you came here?” She started laughing at my question.
    • My question was so funny to her that she held her stomach to balance the body’s vibration.
    • Through my laughter, I managed to ask, “What’s so funny about this question?” “It’s that …” she was still trying to get a hold of her laughter.
    • It’s just that I have never made pickle in my life before!
    • … My mother never asked me to cook or to do any house chores because I was busy with my study.
    • It’s just that I have never made pickle in my life before!
    • … My mother never asked me to cook or to do any house chores because I was busy with my study.
    • She turned her back to me, cleaning some dishes in the kitchen basin, or did she just try to hide her tears?
    • She said,
      Everyone is so proud of my husband now that he is doing well in his field.

That choice

    • What about my own struggle as a Bangladeshi migrant woman in this foreign land?
    • The man was shouting F-words in front of a platform full of people waiting for the same train.
    • And was that not me who had decided to leave her profession after her second child was born; who herself had to make that impossible choice, a choice between academic career and motherhood.
    • It took five years of struggle for me to come back to academia, but that’s another story for another time.
    • Did Australia help her realise her dreams, or did it become the graveyard of her dreams?

Minerva Surgical to Announce First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, April 18, 2023

SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023.

Key Points: 
  • SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023.
  • In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Recent Events section of the company’s website at http://ir.minervasurgical.com .
  • A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, April 5, 2023

Full Year 2022 and Recent Highlights:

Key Points: 
  • Full Year 2022 and Recent Highlights:
    Bolstered balance sheet with cash and cash and cash equivalents of $21 million.
  • Acquisition of Nora Pharma Inc. in October 2022, giving the Company 49 prescription drugs on the market in Canada.
  • Increased sales from $228,426 in 2021 to $4,345,603 in 2022, largely due to inclusion of the 72 days of Nora Pharma operations, the time since the closing of the acquisition.
  • “We are delighted with our accomplishments in 2022 and look forward to continuing to build value for our shareholders in 2023 and beyond,” said Camille Sebaaly, CFO of Sunshine Biopharma.

Healthier Choices Management Corp. Reports Fourth Quarter 2022 Financial Results and Full Year Fiscal 2022 Results

Retrieved on: 
Monday, April 3, 2023

HOLLYWOOD, FL, April 03, 2023 (GLOBE NEWSWIRE) -- Healthier Choices Management Corp. (OTC Pink: HCMC) today announced financial results for the fourth quarter and the twelve-months ended December 31, 2022.

Key Points: 
  • Fourth Quarter 2022 Results and Recent Highlights:
    Net sales from operations for the three-month period ended December 31, 2022, amounted to $12.3 million, compared to $3.2 million, an approximately $9.1 million and 285% increase versus the same period in 2021.
  • It should be noted that over $1.1 million in non-recurring expenses were incurred during the three-month period ended December 31, 2022.
  • It should be noted that over $3.0 million in non-recurring charges were incurred during the twelve-month period ended December 31, 2022.
  • The following table sets forth our Condensed Consolidated Statements of Operations for the three and twelve-months ended December 31, 2022 and 2021: